A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

This study analyses the efficacy and safety of amlotinib as a study drug in the treatment of HER-2 negative advanced breast cancer in the real world, including the number of treatment lines, monotherapy, combination therapy, and different molecular subtypes of breast cancer. Evidence-based medicine evidence for clinicians. Although the clinical application of amlotinib in breast cancer treatment is a supra-indication drug, in view of its high safety and possible good efficacy for advanced breast cancer, some patients have been clinically adopted to try the treatment after communicating with their families. This study provides evidence for the further use of amlotinib in breast cancer treatment by analysing the efficacy and safety of amlotinib in real-world applications.

Sex

All

Inclusion Criteria:

* Imaging or tissue/cell puncture, etc. confirmed recurrent, metastatic breast cancer
* Pathologically confirmed HER-2 negative
* Application of amlotinib treatment until disease progression or toxicity intolerable, or voluntarily give up the continuation of amlotinib treatment,amlotinib application for at least 2 cycles
* The clinical data are basically complete

Exclusion criteria:

* Patients receiving local treatment means such as surgery and radiotherapy
* Patients with combined second primary breast cancer and other primary malignant tumors
* Patients with symptomatic brain metastases